ALK Inhibitors in the Treatment of ALK Positive NSCLC.

Front Oncol · 2018 · PMC6333640 · PMID 30687633

Europe PMC DOI

hedged sentences

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp < 0.00001actually significant

Overall, highly significant PFS was achieved with ALK inhibitors compared to chemotherapy (HR 0.42 [0.35, 0.50; p < 0.00001]) (Figure 2 ).

also in 132,142 other papers

close to being statistically significantno p-value reported

Despite such a huge crossover in first line comparison, a numerical advantage close to being statistically significant was yet achieved.

also in 228 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.